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The skeletal muscle ryanodine receptor (RyR1), i.e., the Ca2+ channel of the sarco/endoplasmic reticulum (S/ER), and the
voltage-dependent calcium channel Cav1.1 are the principal channels involved in excitation-contraction coupling in skeletal
muscle. RYR1 gene variants are linked to distinct skeletal muscle disorders, including malignant hyperthermia susceptibility
and central core disease (CCD), mainly with autosomal dominant inheritance, and autosomal recessive myopathies with
a broad phenotypic and histopathological spectrum. The age at onset of RYR1-related myopathies varies from infancy
to adulthood. We report the identification of four RYR1 variants in two Italian families: one with myopathy and vari-
ants c.4003C>T (p.R1335C) and c.7035C>A (p.S2345R), and another with CCD and variants c.9293G>T (p.S3098I) and
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT (p.F4924 V4925insRQGVALLPFF). We demonstrate that, in
patient-specific lymphoblastoid cells, the c.4003C>T (p.R1335C) variant is not expressed and the in-frame 30-nucleotide insertion
variant is expressed at a low level. Moreover, Ca2+ release in response to the RyR1 agonist 4-chloro-m-cresol and to thapsigargin
showed that the c.7035C>A (p.S2345R) variant causes depletion of S/ER Ca2+ stores and that the compound heterozygosity for
variant c.9293G>T (p.S3098I) and the 30-nucleotide insertion increases RyR1-dependent Ca2+ release without affecting ER Ca2+
stores. In conclusion, we detected and functionally characterized disease-causing variants of the RyR1 channel in patient-specific
lymphoblastoid cells.
This paper is dedicated to the memory and contribution of Luigi Del Vecchio.
1. Introduction
The RYR1 gene (OMIM ∗180901) encodes the skeletal mus-
cle ryanodine receptor (RyR1), which is the Ca2+ release
channel of the sarcoplasmic reticulum (SR). RyR1 and the
voltage-dependent L-type calcium channel Cav1.1 are the
two principal channels involved in excitation-contraction
coupling in skeletal muscle and are mechanically coupled.
The activation of Cav1.1 by depolarization induces RyR1 to
open and release calcium from the SR; this mechanism is
called “depolarization-induced Ca2+ release.” RyR1 is also
regulated by specific proteins, Ca2+, Mg2+, and ATP, and by
pharmacological ligands.
Mutations in the RYR1 gene are linked to several dis-
tinct skeletal muscle disorders, i.e., malignant hyperthermia
susceptibility (MHS), central core disease (CCD), exer-
tional rhabdomyolysis, King Denborough syndrome, late-
onset axial myopathy, and congenital “core-rod myopa-
thy,” all mainly with an autosomal dominant inheritance,
whereas it is linked to subgroups of multiminicore disease
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(MMD), congenital fiber type disproportion, and centronu-
clear myopathy with an autosomal recessive inheritance [1].
The age at onset of RYR1-related myopathies varies from
infancy to adulthood. In recent years, autosomal reces-
sively inheritedmyopathies associatedwith sequence variants
(SVs) in the RYR1 gene and with a broad phenotypic and
histopathological spectrum have been reported [2–6].There-
fore, it has been suggested that RYR1-related myopathies are
probably the most frequent form of congenital myopathies
in several populations [3, 7, 8]. Malignant hyperthermia
susceptibility is an autosomal dominant pharmacogenetic
disorder that occurs in genetically predisposed subjects
during general anesthesia and is induced by commonly
used volatile anesthetics and/or the neuromuscular blocking
agent succinylcholine. Triggering agents cause an abnormal
increase in intracellular Ca2+ in skeletal muscle. A malignant
hyperthermia (MH) attack, unless immediately recognized
and treated with dantrolene, could be fatal. The gold stan-
dard for MH susceptibility (MHS) diagnosis is an in vitro
contracture test (IVCT) on fresh muscle biopsies in which
the differential contractile responses of MH-normal (MHN)
and MHS muscles to caffeine and halothane are recorded
[9, 10]. In about 70% of affected families, MHS is caused by
mutations in the RYR1 gene. Moreover, RYR1 SVs, associated
or possibly associated with MHS status, have been identified
in patients who experienced exertional or stress-induced
rhabdomyolysis, which are events similar to those occurring
in MHS patients after exposure to anesthetics [11, 12]. Less
than 1% of MHS cases are caused by mutations in the
CACNA1S gene that encodes the 𝛼1S subunit of the voltage-
dependent L-type calcium channel of the skeletal muscle,
Cav1.1 [13–15].
Central core disease (MIM #117000) is a rare congenital
myopathy characterized by muscle hypotonia and general-
ized weakness, delayed motor milestones, and skeletal mal-
formations such as scoliosis and hip dislocation. However,
marked clinical variability, often within the same family, has
been recognized [16]. CCD is usually dominantly inherited,
but some forms with more severe presentations have been
reported to be associated with recessive inheritance [16].
Symptoms are usually present in infancy but may appear at
any stage of life. The diagnosis of CCD is established by the
histological analysis of muscle samples that usually reveals
several central amorphous areas with sarcomere disorganiza-
tion (“cores”) that lack mitochondria and oxidative enzyme
activity in type 1 fibers. CCD patients are at risk of MHS;
in fact, some patients experience clinical episodes of MH
and/or were typed MHS by IVCT [17]. The identification
and functional characterization of novel RYR1 SVs are an
aid to the diagnosis of MHS and CCD and to the eluci-
dation of the molecular basis of the distinct pathophysio-
logical characteristics of each RYR1-related disorder (drug-
dependent hyperactivity in MHS, muscle weakness and core
development in CCD, minicores in MMD, and histological
anomalies in other RYR1-related myopathies). Thus far, more
than 300 missense SVs have been identified in the RYR1 gene
(http://evs.gs.washington.edu/EVS/). Various methods have
been developed to characterize the function of RyR1 variants
[18–26]. The demonstration that the kinetic properties of
the RyR1 channel are altered in MHS or in myopathic
patients implicates the mutated channel in the pathogenesis
of MHS and myopathies. Furthermore, genetic analysis can
reveal cases of genotype/phenotype discordance, which are
characterized by the presence of a causative mutation and an
MHN-typed phenotype by IVCT [27, 28].
In this article, we report the identification of four RYR1
SVs and the characterization of Ca2+ release in the lym-
phoblastoid cells of patients. We also report the results of
expression studies in the same cell lines, demonstrating that
some variant alleles are not expressed or are expressed at a
low level, which may give some clues about the etiology of
the disease.
2. Materials and Methods
2.1. Patients and IVCT Test. Informed consent for the sam-
pling and the research use of biological material, for the
genetic analysis, for the IVCT, for the treatment of personal
information, and for the publication of this report was
obtained from each patient according to the procedures
established by theDeclaration ofHelsinki, the Italian law, and
the Ethical Committee of the University of Naples “Federico
II.”
2.2. Family NA-36. Patient 461 is a five-year-old boy who
was referred to our Centre for an MH attack. At the age
of two years, after anesthesia with sevoflurane for bilateral
cryptorchidism, the creatine kinase (CK) level increased to
719 U/L (normal range 0-190 U/L) and the temperature to
40.2∘C.Dantrolene was administered. At his last neurological
evaluation, the patient exhibited dysmorphic facial features
consisting of a prominent forehead, anteverted nares, arched
palate, mandibular hypoplasia, palpebral ptosis, moderate
widespread proximal muscle hypotrophy and hypotonia, and
lumbar hyperlordosis. Myopathy was diagnosed. Patient 460
is the father of patient 461 (Figure 1(a)).
He exhibited short stature, mandibular prognathism,
prominent eyebrows, sunken orbits, left testicular hypotro-
phy, weak and symmetrical osteotendinous reflexes, mild
hypotrophy of the pelvic girdle and limb muscles, and,
since childhood, kyphoscoliosis and thoracic lordosis. The
electromyography (EMG) showed mild myopathic features.
After the detection of high plasma levels of CK, ALT, and
LDH, he underwent a biopsy of the biceps brachii muscle that
revealed variability of fiber morphology with the presence
of hypotrophic and atrophic (30%) fibers, a mild increase in
connective tissue (10%) and rare ghost (5%) and degenerating
(10%) fibers (Supplementary Figure S1). Overall, the histolog-
ical findings were consistent with the diagnosis of primary
myopathy. The IVCT failed because of the slow twitch of
muscle fibers. Patient 461's mother (463, Figure 1(a)) does not
show any sign of myopathy or facial dysmorphism and was
typed MHN by IVCT.
2.3. Family NA-39. Patient 425 is a 46-year-old woman.
She had delayed motor development with independent
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Figure 1: (a) Pedigree of the NA-36 family. Filled symbols indicate myopathy. The asterisk indicates the patient who experienced an MH
episode; N indicates that the subject has been typedMHNby IVCT. (b) Pedigree of the NA-39 family. Filled symbols indicate CCDmyopathy;
the white symbol indicates a CCD-negative individual and the question mark indicates nontested individuals.
ambulation at five years, short stature, and severe dor-
sal scoliosis and lumbar lordosis since childhood. At the
age of 17 years, she underwent a muscle biopsy and was
diagnosed with CDD. At that age, restrictive respiratory
insufficiency was observed, while the cardiologic assess-
ment was normal. At her last neurological examination
(2014), the patient had myopathic facies, mild weakness of
the neck flexors, widespread muscle hypotrophy that was
more severe in the proximal segments of limbs, waddling
gait, equinus feet, lumbar hyperlordosis, and dorsolumbar
right convex scoliosis; tricipital osteotendinous reflexes were
absent. Ankle joints were blocked and heel walking was
impossible. Gowers' maneuver was positive and the patient
needed bilateral support to get up from a chair. Patient 521
is a 50-year-old man who has a clinical picture similar to
that of his sister (patient 425), namely, myopathic facies,
widespread muscle hypotrophy that was more severe in
the proximal segments of limbs, waddling gait, lumbar
hyperlordosis, dorsolumbar right convex scoliosis, and pos-
itive Gowers' maneuver. Patient 522, an 18-year-old woman,
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daughter of patient 521, had positive Gowers' maneuver,
hyposthenia of the neck flexor, tricipitis and quadricipital
muscles, mild hyposthenia of the shoulder girdle mus-
cles,mild hyperlordosis, diminished tricipital osteotendinous
reflexes, and absent patellar reflexes. A CCD diagnosis was
advanced. Subject 530, the 21-year-old son of patient 521
at his last neurological examination (2016), was clinically
asymptomatic. The clinical phenotype of the subject 531, the
mother of patients 425 and 521 (Figure 1(b)), has not been
ascertained.
2.4. IVCT. The standardized European IVCT was carried
out as described elsewhere [29]. An increase in force of at
least 0.2 g after exposure to either 2% halothane or 2 mM
caffeine indicates MHS. Contracture thresholds at higher
concentrations than these are considered normal.
2.5. Mutation Screening. Total RNA was extracted from
peripheral blood lymphocytes using the QIAmp RNA Blood
Mini kit (Qiagen, Hilden, Germany). Total RNA (2.5 𝜇g)
was used to synthesize cDNA using the SuperScript VILO
cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA). The
RYR1 cDNA was subsequently amplified in 49 overlapping
fragments, using primers (Table S1) designed on the human
RYR1 transcript sequence (NM 000540.2), and sequenced
with dye-terminator chemistry (Applied Biosystems) using
an ABI3100 automated sequencer (Applied Biosystems,
USA). Genomic DNA (gDNA) was extracted with the
“Nucleon” procedure (Amersham, Little Chalfont, UK) from
peripheral blood samples and immortalized lymphoblastoid
cells. PCR primers for the amplification of the 106 exons
of the RYR1 gene and the intron boundary sequences
were designed on the human RYR1 genomic sequence
(ENSG00000196218, NG 008866.1, accession numbers) as
described elsewhere [25]. Nucleotide numbering was based
on the reference cDNA sequence (NM 000540.2). Indirect
evidence of the pathogenicity of the variants identified
was based on the following conditions: the absence in 100
chromosomes from normal individuals of the same ethnic
group checked by denaturing high-performance liquid
chromatography (DHPLC) analysis as previously described
[25]; the absence in the 1000 genomes resequencing
project (https://www.ncbi.nlm.nih.gov/variation/tools/1000-
genomes); the prediction of their pathological character
using three programs, namely, PMut (http://mmb.pcb.ub.es/
PMut/), SIFT (http://sift.jcvi.org/), and PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/); the population allele
frequencies determined using the ExAC Browser (Beta)
database (http://exac.broadinstitute.org/) [30]; the potential
pathogenic role of the variants identified using Alamut Focus
version 0.9 (Interactive Biosoftware, Rouen, France). Alamut
is a licensed software package available from Interactive
Biosoftware (https://www.interactive-biosoftware.com).
Secondary structure and hydropathy plot were predicted by
the Emboss’ Garnier software (http://www.bioinformatics.nl/
cgi-bin/emboss/garnier/) and the Kyte & Doolittle plot
(http://web.expasy.org/protscale/), respectively.
2.6. Mononuclear Cells and EBV-Transformed Cell Lines.
Whole blood was collected in EDTA-treated tubes, and
mononuclear cells were isolated by centrifugation on Ficoll-
Hypaque (Sigma-Aldrich, Saint Louis, MO, USA) den-
sity gradient. For infection with Epstein-Barr virus (EBV),
mononuclear cells were exposed to supernatants of the B95.8
cell line, according to standard procedures [31]. Cells were
cultured in Iscove’s Modified Dulbecco’s Medium (Sigma-
Aldrich, Saint Louis, MO, USA) supplemented with 20%
fetal bovine serum (Hyclone Laboratories Inc., Logan, UT,
USA) and 1% L-glutamine (Sigma-Aldrich, Saint Louis, MO,
USA). The presence of RYR1 SVs in the EBV-immortalized
lymphoblastoid cells from patients was confirmed by DNA
sequencing. Compared to cell lines carrying other RYR1 SVs,
the cell culture carrying the insertion variant prematurely
displayed increased average cycle times and increased cell
size, which are characteristic of replicative senescence in
cultured cells [32]. At this stage, the cells were discarded.
2.7. Transcription Analysis. Total cellular RNA was extracted
from EBV-immortalized B lymphocytes (1 x 107 cells) using
the QIAmp RNA BloodMini kit (Qiagen, Hilden, Germany).
The SuperScript III first-strand synthesis system (Invitrogen,
Carlsbad, CA, USA) was used to synthesize first-strand
cDNA from 2.5 𝜇g of total RNA. Real-time PCR reactions
were carried out in 10 𝜇l reaction mixture containing cDNA
(serial dilution 1:5, 1:10, 1:20, 1:40), 0.5 𝜇M of each primer,
and 1x Platinum SYBR Green qPCR SuperMix (Invitro-
gen, Carlsbad, CA, USA). The GAPDH (glyceraldehyde-
3-phosphate dehydrogenase, NM 001289745) was used as
reference gene. Primers for GAPDH cDNA amplification
were GAPDH- F: TGGTATCGTGGAAGGACTCAT and
GAPDH- R: GAAGGCCATGCCAGTGAG (amplicon of 104
bp). Primers for RYR1 cDNA amplification were RYR1-F:
TCAACACGCCGTCTTTCCCT (c.14250-14269) and RYR1-
R: GTTGGGCTTGCGCTCATTGT (c.14410-14391) (ampli-
con of 161 bp). The RYR1-F primer spans the 96-97 exon
junction. The real-time PCR reactions were run in triplicate
on a 7900 HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA) using the following thermal
profile: 50∘C for 2 min, denaturation at 95∘C for 10 min,
40 cycles with denaturation at 95∘C for 15 s, annealing at
60∘C for 30 s, and polymerization at 72∘C for 30 s. A single
fluorescence measurement was conducted at the end of the
72∘C extension step. A melting curve program (94∘C for 15 s,
60∘C for 30 s, and 95∘C for 15 s with continuous fluorescence
measurements) was used to verify the uniformity of the
PCR products. Derivative melting curves generated only
a single peak, indicating that no nonspecific products or
primer-dimers were present. Cycle threshold (Ct) values were
determined using the software RQ manager 1.2 provided by
the manufacturer (Applied Biosystems). The relative gene
expression was calculated using the 2-ΔΔCt method [33].
Semiquantitative PCR reactions were carried out to ana-
lyze the differential expression of the RYR1 variant alleles
in family NA-39 [34]. The following primers for RYR1 and
reference ACTB (𝛽 actin, NM 001101.3) cDNAs were used:
RYR1- F: TCACATGTACGTGGGTGTCC (c.14658-14677)
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and RYR1-R: GCACTTGGTCTCCATATCCTCA (c.14877-
14856, spanning the 103-104 exon junction); 𝛽-actin F:
CGTCTTCCCCTCCATCGT and 𝛽-actin R: TGTTGGCG-
TACAGGTCTTTG.The F primers were labeled with fluores-
cent dyes PET and VIC, for the RYR1 and the ACTB cDNAs,
respectively. RT-PCR products (1 𝜇L) were separated on the
ABI PRISM 3130 Genetic Analyzer (Applied Biosystems)
at 15 kV, at 60∘C for 25 min using the POP-7 polymer.
Electrophoresis data were collected using the ABI PRISM
3130 Data Collection Software Application v1.1 (Applied
Biosystems) and the areas of the electrophoresis peaks were
calculated for each specific PCR product using ABI PRISM
GeneScans Analysis Software v3.7.1 (Applied Biosystems).
2.8. Western Blot Analysis. The amount of the RyR1 protein
in lymphoblastoid cells was determined by semiquantitative
Western blot analysis using anti RyR1 rabbit polyclonal
primary antibodies (kindly provided by Prof. V. Sorrentino,
University of Siena, Italy) and anti 𝛼-actinin antibodies
(Santa Cruz Biotechnology, Dallas, TX, USA) as previously
described [35], and a secondary HRP-conjugated goat anti-
body (Bethyl Laboratories Inc., Montgomery, TX, USA).
Specific antigen detection was performed using a chemilumi-
nescent HRP substrate and quantified with a ChemiDoc XRS
apparatus (Biorad, Hercules, CA, USA) and the Quantity 1
software (Biorad, Hercules, CA, USA).
2.9. Calcium Release Assay. The Ca2+ flux was measured by
flow cytometry using the Fluo-3 and Fura Red Ca2+ sensitive
fluorophores (Thermo Fisher Scientific,Waltham,MA, USA)
according to Bailey and collaborators [36]. The fluorescence
intensity of Fluo-3 increases upon binding Ca2+ and that of
Fura Red decreases. Therefore, the Fluo-3/Fura Red fluores-
cence signal ratio is a ratiometric procedure for the analysis of
intracellular Ca2+ fluxes. EBV-immortalized B lymphocytes
were incubated with 2.6 𝜇M Fluo-3 AM and Fura-Red
AM at 37∘C and 5% CO2 for 30 min in Iscove's medium
supplemented with 0.1% BSA (Sigma-Aldrich) and 1% L-
glutamine. Subsequently, cells were resuspended in HBSS
medium without Ca2+, 1 mM EGTA (Sigma-Aldrich) at 1x106
cells/ml. A BD FACSAria cell sorter (BD, Franklin Lakes, NJ,
USA) was used to measure Ca2+ fluxes. Intracellular dyes
were excited at 488 nmand the emission signalswere detected
with the 530/30 nm (Fluo-3) and 610/20 nm (Fura Red) filters.
Fluo-3, Fura-red, and Fluo-3/Fura-red emission signals were
recorded for 2 min before stimulation to obtain baseline flu-
orescence values. Subsequently, 4-chloro-m-cresol (4-CmC)
(Sigma-Aldrich) or thapsigargin (TG) (Sigma-Aldrich) were
added to the cell suspension and the fluorescence signals
were recorded for 5 min. A kinetic analysis of cell reactions
was performed by splitting the Fluo-3 and Fura-red dot plot
displays (fluorescence intensity vs time) into 50 gates. In
each gate, the mean fluorescence values for Fluo-3 and Fura-
red were determined using the Becton-Dickinson Analysis
software. Microsoft Excel software (Microsoft Corporation,
Redmond, WA, USA) was used to correct Fluo-3 and Fura-
red signals for baseline values and to calculate Fluo-3/Fura
Red ratios.The cellular responses to the drug (4-CmC or TG)
were measured by integrating over time the Fluo-3/Fura Red
ratio signals by SigmaPlot 11 software (SPSS Science, Chicago,
IL, USA).
2.10. Statistical Analysis. Data were collected for each exper-
imental condition from at least three independent exper-
iments. To assess the statistical significance of intergroup
differences (p<0.05), the standard two-tailed Student’s t-test,
or the one-way analysis of variance followed by Dunnett’s
test, was used. Results are presented as mean ± standard
error of the mean (SEM). Statistical analysis and data plots
were performed using SigmaPlot 11 software (SPSS Science,
Chicago, IL, USA). Differences were considered significant
when p<0.05.
3. Results
3.1. Identification and Characterization of RYR1 SVs. The
screening of the entire RYR1 cDNA and coding gDNA
sequences revealed two RYR1 SVs at the heterozygous state
in familyNA-36 (Figure 1(a)). Substitutions c.4003C>T (exon
28, p.R1335C) and c.7035C>A (exon 44, p.S2345R) were
identified in patient 460. Variant c.4003C>T (p.R1335C) was
identified on gDNAbut not on cDNA (Figures 2(a) and 2(b)).
Accordingly, the c.7035C allele, which carries the c.4003T
variant upstream, was barely detectable in cDNA of patient
460 (Supplementary Figure S2). No SNPs were detected on
gDNA at cDNA primer annealing sites (cDNA amplification
reaction 6, Supplementary Table S1), thereby excluding allele
drop out in the cDNA PCR reaction.
Patient 461, who experienced an MH crisis after anesthe-
sia with sevoflurane, inherited the c.7035C>A (p.S2345R) SV
from his father (460) (Figure 1(a)).
The c.7035C>A (p.S2345R) SV was not found in
100 chromosomes from normal individuals of the same
ethnic group by denaturing DHPLC analysis or in the
1000 genomes resequencing project (https://www.ncbi.nlm
.nih.gov/variation/tools/1000genomes); this variant has been
identified in a family withMHS andmyopathy (hyperlordosis
and toe walking) [5] and is predicted to be pathological
by three prediction software programmes (PMut,
http://mmb.pcb.ub.es/PMut/; SIFT, http://sift.jcvi.org/;
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2). Variant
c.4003C>T (p.R1335C) was not found in 100 chromosomes
from normal individuals of the same ethnic group
by DHPLC analysis and is reported in the ExAC
database (http://exac.broadinstitute.org/) with a minor
allele frequency (MAF) of 4.1⋅10−5. Moreover, in silico
analysis using the Alamut software package (https://www
.interactive-biosoftware.com) showed that the c.4003C>T
substitution alters the Exon Splicing Enhancer distributions
and that allele c.4003T has a higher chance of exon 28
skipping than allele c.4003C (Supplementary Figure S3).
Similarly, two RYR1 SVs at the heterozygous state were
identified by screening the entire RYR1 cDNA and coding
gDNA sequences of patient 425 who is the CCD proband
of family NA-39 (Figure 1(b)), namely, the c.9293G>T
(exon 63, p.S3098I) substitution and the insertion variant
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gDNA
C > T
ACT TCGCCGNGTCCAAAAGCATCAG
RYR1c.4003C>T (p.R1335C)
Patient 460
(a)
cDNA
ACT TCGCCGCGTCCAAAAGCATCAG
RYR1c.4003C>T (p.R1335C)
Patient 460
(b)
gDNA
CCT TCT TCT TCT TCGTCATCGTCATCCTGT TGGCCATCATCCAGG
CCT TCT TCT TCT T TAGACAGGGTGT TGCTCTGT TGCCCT TCT TCG
RYR1c.14771_14772ins30nt
(p.F4924_V4925insRQGVALLPFF) 
Patient 425
(c)
cDNA
CCT TCT TCT TCT TCGTCATCGTCATCCTGT TGGCCATCATCCAGG
RYR1c.14771_14772ins30nt 
(p.F4924_V4925insRQGVALLPFF) 
Patient 425
(d)
Figure 2: Sequence analysis of the variant RYR1 c.4003C>T (p.R1335C) ((a) and (b)) in patient 460 and the variant RYR1
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT (p.F4924 V4925insRQGVALLPFF) ((c) and (d)) in patient 425 from
gDNA ((a) and (c)) and cDNA ((b) and (d)) isolated from the patient’s lymphocytes. The arrows in the nucleotide sequences indicate the
position of the mutation; the sequence of the insertion in patient 425 is underlined.
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCC
TTCTT (exon 102, p.F4924 V4925insRQGVALLPFF). In
patient 425, sequence analysis showed a disequilibrium
between the cDNA levels of the wild-type and of the
variant sequences (Figure 2(d)). In fact, both the cDNA
and the gDNA electropherograms showed two overlapping
sequences, but, in the cDNA, the peaks of the mutated
sequenceweremuch lower than those of thewild type.On the
contrary, in the gDNA, the heights of the peaks of themutated
sequence were similar to those of the wild type (Figure 2(c)).
TwoARMS reactionswith two insertion-specific primer pairs
designed to amplify the allele with insertion confirmed the
presence of the insertion variant (Supplementary Figure S4).
Similar electrophoretic patterns were obtained with
cDNA and gDNA from patient 521, who has the same
RYR1 haplotype as his sister (patient 425), and his
children (patients 522 and 530) (data not shown),
who inherited only the insertion variant from the
father (Figure 1). These data indicate low levels of the
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCT
TCTT (p.F4924 V4925insRQGVALLPFF) mutated mRNA
molecules. Interestingly, we found that the first 25 nt of
the 30 nt inserted sequence corresponds to an inverted
and complementary sequence located at RYR1 intron 105
(158553-158529, NG 008866.1, Supplementary Figure S5).
Sequencing of the entire RYR1 genomic region spanning
from intron 102 to exon 106 of CCD patient 425 (data
not shown) did not reveal a deletion of the transposed
sequence or any additional SVs in the mutated DNA
that could have generated rearrangement breakpoints.
Therefore, we hypothesized that this insertion variant
could have arisen from a replicative transposition involving
the intron sequence replication and its inversion and
transfer to the new site. The 10-amino acid insertion variant
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCT
TCTT (F4924 V4925insRQGVALLPFF) lies in the S6
transmembrane segment (amino acids 4914-4937)
of the RyR1 structure model proposed by Zalk and
collaborators [37]. Secondary structure prediction using
the Emboss Garnier software (http://www.bioinformatics
.nl/cgi-bin/emboss/garnier/) and the analysis of hydropathy
using the Kyte & Doolittle method (http://web.expasy.org/
protscale/) showed that the 10-amino acid insertion causes
an interruption in an 𝛼-helix structure (Supplementary
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Figure S6) and modifies the hydropathy plot of the S6
segment (Supplementary Figure S7). The c.9293G>T
(p.S3098I) variant identified in family NA-39 was not
detected in 100 alleles of normal individuals of the
same ethnic group by DHPLC analysis or identified as
a polymorphism in the 1000 genomes sequencing project
(https://www.ncbi.nlm.nih.gov/variation/tools/1000genom-
mes) but is reported in the ExAC database (http://exac
.broadinstitute.org/) with a MAF of 8.2⋅10−6 and probably
affects the function of the RyR1 channel. In fact, the
c.9293G>T (p.S3098I) substitution was predicted to be
pathological by three software programmes (PMut, http://
mmb.pcb.ub.es/PMut/; SIFT http://sift.jcvi.org/; PolyPhen-2
http://genetics.bwh.harvard.edu/pph2).
3.2. Transcription Analysis. The RYR1 gene is expressed in
human B-lymphocytes [38] and Ca2+ homeostasis is altered
in B cells of MHS and CCD patients. Therefore, this cell sys-
tem can be used as amodel to test the effect ofRYR1 SVswhen
muscle samples are not available. We, therefore, analyzed the
expression of the RYR1 variants identified in retrotranscribed
RNA samples isolated from patients' immortalized B lym-
phocytes. In family NA-36, real-time PCR analysis showed
that the total RYR1 mRNA levels in patient 460, carrying
variants c.4003C>T (p.R1335C) and c.7035C>A (p.S2345R),
and in patient 461, carrying variant c.7035C>A (p.S2345R),
were about 40% (n=11, p-value < 0.001) and 82% (n=11, p-
value > 0.05), respectively, of the levels of the control sample
(Figure 3(a)). In family NA-39, the total RYR1 mRNA level
of patient 521, carrying variants c.9293G>T (p.S3098I) and
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCT
TCTT (p.F4924 V4925insRQGVALLPFF), did not differ sig-
nificantly from the levels of the control sample (81%, n=8,
p-value > 0.05) (Figure 3(a)). As shown in Figure 2(d), the
electrophoretic patterns of cDNA sequencing performed on
patients of family NA-39 indicated low expression of the
30 nt insertion allele (Figure 2(d) and data not shown).
Therefore, we measured RYR1 mRNA levels of the 30 nt
insertion variant by a semiquantitative PCR analysis [34]
on cDNA of patient 425 (family NA-39). To this aim, we
amplified the RYR1 fragment containing the insertion site
(c.14658-14877). The amplicons from cDNA, separated by
capillary gel electrophoresis, revealed two peaks, one of 220
bp and the other of 250 bp, which correspond to the expected
lengths of the RYR1 alleles without and with the 30 nt
insertion, respectively. The total RYR1 mRNA levels of CCD
patient 425 were about 89% of those of the control (n=3).
In particular, the RYR1 mRNA alleles with and without the
30 nt insertion represented about 13% and 76%, respectively,
of the total RYR1 mRNA levels (Figure 3(b)). These data
demonstrate that the levels of mRNA with the insertion
variant are low in CCD patient 425, but this unbalanced
expression does not basically affect the total RYR1 expression
levels. Accordingly, the RyR1 protein content determined
by semiquantitative Western blots (Figures 3(c) and 3(d))
in lymphoblastoid cells from patient 425 was not statisti-
cally different from that of the control (n = 3, p-value >
0.05).
3.3. Calcium Release Measurements. We investigated Ca2+
release in response to stimulation with 4-chloro-m-cresol (4-
CmC) or thapsigargin (TG) in immortalized B-lymphocytes
from patients 460, 461 (family NA-36), and 425 (family NA-
39) and from two unrelated control cell lines using a flow
cytometry technique. No statistically significant difference
was assessed between the calcium releasemeasurements from
the two control cell lines. Therefore, data from the two
control cell lines have been averaged and presented in the
plots as a single control group. 4-CmC specifically activates
the RyR1 channel [39, 40]. TG is a pump blocker of the
sarco/endoplasmic reticulum calcium ATPase (SERCA) that
hinders Ca2+ uptake into the sarco/endoplasmic reticulum
(SR/ER), thereby allowing passive leakage of Ca2+ from the
SR/ER and Ca2+ store [41, 42]. As shown in Figure 4(a), 4-
CmC-triggered and TG-induced Ca2+ releases were signif-
icantly lower in immortalized B-lymphocytes from patients
460 and 461 (family NA-36) than in control cells. Moreover,
resting intracellular calcium concentration in immortalized
B-lymphocyte from patients 460 and 461 was not different
from controls (Supplementary Figure S8; p >0.05). Patient
460 expressed only the RYR1 c.7035C>A (p.S2345R) allele,
whereas patient 461 expressed the RYR1 wt and the RYR1
c.7035C>A (p.S2345R) alleles. Given the finding that the
signal obtained with the SERCA blocker reflects the size
of the rapidly releasable intracellular Ca2+ stores [43], our
results indicate depletion of the Ca2+ store. However, Ca2+
release triggered by 4-CmC, expressed as a percentage of the
TG-induced Ca2+ release [44], was significantly higher in B
lymphoblastoid cells from patient 460 (from 400 to 1000 𝜇M
4-CmC) and frompatient 461 (at 1000 𝜇M4-CmC) versus the
controls (Figure 4(b)).The higher sensitivity to 4-CmCof cell
lines from patient 460 versus the control also emerges from
the shift to the left of the dose-response curve (Figure 4(b)).
Ca2+ release triggered by 600-1000 𝜇M 4-CmC was
significantly higher in immortalized B-lymphocytes
from patient 425 (family NA-39), who expressed the
RYR1 c.9293G>T (p.S3098I) and the RYR1 c.14771
14772insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT
(p.F4924 V4925insRQGVALLPFF) variant alleles, than in
the control cells, whereas the TG-induced Ca2+ release
did not differ significantly (Figure 4(c)). Moreover, the
dose/response curve of the cells from patient 425 showed
a shift to the left compared to the curve from the controls
(Figure 4(d)). Resting intracellular calcium concentration
in immortalized B-lymphocyte from patients 425 was not
different from controls (Supplementary Figure S8; p>0.05).
4. Discussion
Here we report two Italian families, one with myopathy
and another with CCD, associated with RYR1 variants and
RYR1 unbalanced expression in lymphoblastoid cells. The
expression of the c.4003C>T variant (family NA-36), which
would correspond to the p.R1335C substitution, was abol-
ished (Figures 2(b) and 3(a), Supplementary Figure S2). The
c.4003T variant is predicted to have a higher chance of exon
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Figure 3: Expression ofRYR1 variant alleles. (a) Relative quantification ofRYR1mRNA isolated from immortalized B-lymphocytes of patients
460, 461 (Family NA-36), and 521 (Family NA-39. Real-time PCR was performed on cDNAs of patients and of a control. GAPDH was used
as reference gene. The relative expression was calculated using the 2-ΔΔCt method. Data are presented as mean ± standard error of the mean
(SEM). Statistical analysis was performed by one-way analysis of variance followed by Dunnett’s test (∗p< 0.05). (b) To analyze the relative
expression of the two variant alleles identified in family NA-39, the PCR products from cDNAs of patient 425 were analyzed by capillary gel
electrophoresis, as described inMaterials andMethods. RYR1mRNA levels in the CCD patient 425 (normalized by 𝛽-actin mRNA levels) are
expressed as percentages of the control. Each experiment was performed in triplicate. Data are presented as mean ± SEM. (c) and (d) RyR1
protein levels of patient 425 determined by semiquantitativeWestern blot. (c) RepresentativeWestern blot. Homogenates fromHEK293 cells
(lanes 1 and 2) as a control not expressing RyR1, from lymphoblastoid cells of patient 425 (lanes 3 and 4), and from the control (lanes 5 and 6)
were loaded on an SDS-polyacrylamide gel and processed as described in Materials and Methods. (d) The RyR1 protein levels in the control
and in patient 425 were normalized by 𝛼-actinin levels. Data are presented as mean of three experiments. Error bars show the SEM. Statistical
analysis was performed by the two-tailed Student’s t-test (p=0.617).
28 skipping. Alternative splice variant lacking exon 28 would
harbor a premature stop codon, thus possibly leading to a
nonsense-mediated mRNA decay [45].
The expression of the c.14771 14772insTAGACAGGG-
TGTTGCTCTGTTGCCCTTCTT (p.F4924 V4925insRQG-
VALLPFF) (family NA-39) variant was reduced to about
13% of that of the control (Figure 3(b)). RYR1 missense
alleles with null or reduced expression, mainly analyzed in
muscle samples, have been reported in patients with RYR1-
related myopathies [4, 46–52]. Epigenetic changes regulating
RYR1 expression have been described in muscle but not in
cultured myotubes [49]. We found that the expression of
missense alleles was reduced in lymphoblastoid cells derived
from our patients; however, our RYR1 expression results
should be verified in skeletal muscle cells. Unfortunately,
muscle samples from patients 460 and 425 were not available
for molecular analyses and the other patients refused to
undergo a muscle biopsy. Interestingly, the total RYR1mRNA
and the total RyR1 protein levels in patients carrying the
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCT
TCTT (p.F4924 V4925insRQGVALLPFF) variant did not
differ significantly from those of the control, which indicates
that cells compensate for the low expression of the insertion
variant allele by increasing the levels of the other RYR1 allele.
RYR1 gene variants have been associated with a vari-
ety of clinical and histopathological phenotypes [1, 53]. In
particular, some SVs are associated with both CCD and
MHS, others only with CCD. Functional characterization of
RYR1 SVs associated with CCD revealed that somemutations
cause leaky RyR1 channels [54–56]; others, mainly those
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Figure 4: 4-CmC-induced Ca2+ release in lymphoblastoid cells from patients 460, 461 ((a) and (b)), and 425 (c) and (d))
expressing the RYR1 c.7035C>A (p.S2345R ), the RYR1 wt/RYR1 c.7035C>A (p.S2345R), and the RYR1 c.9293G>T (p.S3098I)/RYR1
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT (p.F4924 V4925insRQGVALLPFF) variant alleles, respectively, and two
control cell lines. Cells were stimulated with 4-CmC (200 𝜇M to 1000 𝜇M) or 1 𝜇M TG. Ca2+ release was measured at each concentration by
calculating the integral of the Fluo-3/Fura Red ratio signal over time ((a) and (c)) and expressed as a percentage of the TG-triggered Ca2+
release ((b) and (d)). Experiments were carried out at least three times. Data are reported as mean ± standard error of the mean (SEM).
Statistical analysis of responses of patient cell lines with respect to the average of the two control cell lines was performed by the two-tailed
Student’s t-test or by one-way analysis of variance followed by Dunnett’s test (∗p< 0.05).
located in the pore region, generate an excitation-contraction
uncoupled channel [57, 58]. Moreover, MHS/CCD RYR1
SVs respond to triggering agents with either a reduced or
enhanced Ca2+ increase in response to 4-CmC or caffeine
[54–56, 59]. Furthermore, MHS/CCD mutations located in
the N-terminal and the central region of the RyR1 channel
cause a greater Ca2+-induced Ca2+ release than do MHS
mutations and enhance RyR1 sensitivity to activating Ca2+,
thereby accelerating channel activity [55, 56].
The c.7035C>A (p.S2345R) substitution identified in
family NA-36 was associated with a reduction in the Ca2+
stores of the ER.Moreover, the cell line frompatient 460, who
expresses only the RYR1 c.7035C>A (p.S2345R) allele, shows
a percentage of Ca2+ release triggered by 4-CmC higher than
control and with a dose-response curve shifted to the left
(Figure 4(b)), whereas the cell line from patient 461, who
expresses the RYR1 c.7035C>A (p.S2345R) allele at the het-
erozygous status, shows a percentage of Ca2+ release triggered
10 BioMed Research International
by 4-CmC higher than the control only at a concentration
of 1000 𝜇M 4-CmC (Figure 4(b)). Taken together, these data
imply that the RYR1 c.7035C>A (p.S2345R) variant has a
dominant effect.The c.7035C>A (p.S2345R) variant has been
previously identified in a family with MHS and myopathy [5]
and affects an amino acid residue located in the cytoplasmic
helical domain 1 (residues 2146-2712) between helices 4b
(residues 2325-2340) and 5a (residues 2348-2361) [60]. The
p.S2345T substitution, which affects the same codon, has
been reported in a family with hyperCKemia and reduced
expression of RyR1 [50]. Moreover, the p.S2345R substitution
is located close to the previously identified MHS mutations
p.Asn2342Ser [25], p.Glu2344Asp [61], and p.Ala2350Thr
[24], and MHS/CCD mutation p.Val2346Met [62].
In family NA-39, the compound heterozygosity
condition for variants c.9293G>T (p.S3098I) and c.14771
14772insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT
(p.F4924 V4925insRQGVALLPFF) causes an increase of
RyR1-dependent Ca2+ release after 4-CmC administration
and does not affect ER Ca2+ stores. The insertion variant
lies in the S6 transmembrane segment of the RyR1 structure
model [37] and is predicted to modify this structure
(Supplementary Figures S6 and S7). Although expressed at
low levels, the insertion variant could be statistically present
with at least one monomer in about 46.8% of tetrameric
RyR1 molecules [63] and can influence the behavior of
the channels. Nevertheless, a limit of our study is the
use of nonmuscle cells for the in vitro characterization
of mutants. The c.9293G>T (p.S3098I) substitution was
predicted to have a pathological character and affects a
residue located in a region involved in the homeostasis of
intracellular calcium (amino acids 3770-4007) [64]. On
the basis of our experiments, we could not discriminate
between the effects of the two variants. Unfortunately,
lymphoblastoid cell lines from patients 522 and 530
of family NA-39, carrying only the insertion variant,
could not be used for RyR1 functional assays because
they rapidly showed signs of replicative senescence, and
patients were not available for further blood sampling.
Patient 522 has clear signs of myopathy and a clinical
picture milder than that of patients 425 and 521, who are
composite heterozygous for RYR1 c.9293G>T (p.S3098I) and
c.14771 14772insTAGACAGGGTGTTGCTCTGTTGCCCT
TCTT (p.F4924 V4925insRQGVALLPFF). On the basis
of our experimental evidence, we might speculate that
the RYR1 c.9293G>T (p.S3098I) variant could exacerbate
the myopathic phenotype of these patients. Patient 530,
who carries the same RYR1 genotype as patient 522, at
his last neurological examination did not show signs of
myopathy. Accordingly, variable penetrance and phenotypic
expression have been reported for RYR1-related myopathies
[3, 5, 6, 65–68]. The inheritance of RYR1-related myopathies
is complex, and, moreover, a high phenotypic variability
is associated with some RYR1 SVs, even in patients of the
same family with the same SV and in the same individual
at different ages. This variable degree of penetrance might
arise from differences between individuals with regard
to allele mutant stoichiometry within the tetramer, to
the presence or absence of modifying genes, or to a
combination of both. Exome sequencing analysis could
provide additional information on the genetic background
of family NA-39. Moreover, RYR1 mutations are the most
frequent genetic cause of congenital myopathies and it has
become increasingly clear that many congenital myopathies
are characterized by nonspecific or complex pathological
abnormalities rather than a ‘pure’ muscle pathology pattern
[53].
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